London, United Kingdom

Simak Ali

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2007-2023

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):

Title: Simak Ali: Innovator in CDK Inhibition

Introduction

Simak Ali is a prominent inventor based in London, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that inhibit cyclin-dependent kinases (CDKs). With a total of 6 patents to his name, Ali's work has the potential to impact various therapeutic areas.

Latest Patents

One of Simak Ali's latest patents involves pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds as CDK inhibitors. These compounds are designed to inhibit various CDKs, including CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, and CDK13. The patent outlines pharmaceutical compositions that utilize these compounds to treat disorders associated with CDK activity, such as cancer, viral infections, neurodegenerative disorders, ischaemia, renal diseases, and cardiovascular disorders. The treatment may also include simultaneous or sequential administration of additional active agents, such as aromatase inhibitors or cytotoxic chemotherapeutic agents.

Career Highlights

Throughout his career, Simak Ali has worked with esteemed institutions, including Emory University and Cancer Research Technology Limited. His research has focused on the therapeutic applications of CDK inhibitors, contributing to advancements in cancer treatment and other related fields.

Collaborations

Some of his notable coworkers include James P Snyder and Alexander Bondke. Their collaborative efforts have furthered the research and development of innovative therapeutic solutions.

Conclusion

Simak Ali's contributions to the field of medicinal chemistry, particularly in the area of CDK inhibition, highlight his role as a key innovator. His patents and collaborations reflect a commitment to advancing therapeutic options for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…